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Summary
Inflammatoryboweldisease (IBD), a relatively common
chronic debilitating intestinal illness, is composed of
two broadly defined groups, Crohn’s disease (CD)
and ulcerative colitis (UC). Although several suscepti-
bility genes for CD have been recently described, sus-
ceptibility genes exclusive for UC have not been forth-
coming. Here, we show that receptor protein-tyrosine
phosphatase sigma (PTPRS—encoding PTPs) knock-
out mice spontaneously develop mild colitis that
becomes severe when challenged with two known in-
ducers of colitis. We also demonstrate that E-cadherin
and b-catenin, two important adherens junction pro-
teins involved in maintenance of barrier defense in
the colon, act as colonic substrates for PTPs. Further-
more,weshow that threeSNPs (rs886936, rs17130, and
*Correspondence: drotin@sickkids.ca
7 These authors contributed equally to this work.rs8100586) that flank exon 8 in the human PTPRS gene
are associated with UC. The presence of these SNPs is
associated with novel splicing that removes the third
immunoglobulin-like domain (exon 9) from the extra-
cellular portionofPTPs, possibly alteringdimerization
or ligand recognition.Wepropose that polymorphisms
in the human PTPRS gene lead to ulcerative colitis.
Results and Discussion
The PTPRS-knockout (KO) mice we previously gener-
ated display features consistent with human IBD. Mice
that survive the high neonatal mortality suffer severe
cachexia [1, 2]. Surviving mice appear phenotypically
normal except for mild colitis and significant growth fail-
ure compared to their wild-type (WT) littermates [1, 3]. In
this mouse model, we used the LacZ insert knocked in to
show that PTPRS was expressed in the colon (Figures
S1A–S1C in the Supplemental Data available online).
We confirmed that the PTPRS-KO mice spontane-
ously develop colitis (histological score [4] of 1.5; Fig-
ure 1Ab and Figure S1F) and further described crypt
branching and architectural distortion that was evident
on transmission electron micrographs (Figure S1H).
To determine whether the PTPRS-KO mice were
further susceptible to experimental colitis, we treated
PTPRS-KO mice and wild-type littermates with dextran
sodium sulfate (DSS), an established colitis model [5].
As shown in Figure 1D, the PTPRS-KO mice exhibited
rectal bleeding within 3 days of DSS treatment, and
100% of the KO mice were bleeding by day 6 compared
with 18% of the wild-type group (p < 0.001, log rank test).
In addition, the PTPRS-KO mice lost significantly more
weight (Figure 1Ba) than their littermates (p = 0.01,
Wilcoxon rank sum test). These results, summarized
in a disease activity index (DAI) score [4], show that
the PTPRS-KO mice developed severe colitis in this
experimental model (Figure 1Ca). This effect was most
dramatically seen in the distal colon as severe ulcers
and necrosis (Figure 1Aa) that were significantly worse
in the PTPRS-KO colon, compared with the wild-type
controls (histological score; p = 0.001, Wilcoxon rank
sum test; Figure 1Ab). The PTPRS-KO mice also had
significantly more bacteria translocated to mesenteric
lymph nodes compared to the wild-type (p = 0.009,
Fisher’s exact test; Figure 1E), again emphasizing the
worsening of the existing colitis in these mice.
To further demonstrate that PTPRS-KO mice have an
increased susceptibility to colitis, we used the Citro-
bacter rodentium experimental model of colitis [6]. As
shown in Figure 1Bb, the PTPRS-KO mice showed signif-
icant weight loss, whereas the wild-type mice (and un-
treated PTPRS-KO mice, not shown) continued to gain
weight during the entire experimental period (p < 0.001,
Wilcoxon rank sum test). The PTPRS mice had signifi-
cantly worse median DAI (p < 0.001, Wilcoxon rank sum
test; Figure 1Cb) and histological scores (p < 0.001,
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type littermates.
Transmission electron micrographs showed that the
PTPRS-KO mice challenged with C. rodentium had
increased luminal bacterial colonization (Figure 2A),
especially within the colonic crypts; such an increased
colonization is rarely observed in healthy colons [7].
This finding was supported by the decrease in bacterial
clearance found in the PTPRS-KO mice compared to the
wild-type (p < 0.04, Fisher’s exact test; data not shown).
Furthermore, the presence of luminal bacteria was asso-
ciated with damage to the epithelial surface, resulting in
increased shedding (anoikis) of epithelial cells into the
gut lumen (Figure 2B). Anoikis is known to be increased
in IBD and is associated with early loss of E-cadherin in
enterocytes [8, 9].
We recently identified N-cadherin and b-catenin as
in vivo substrates for PTPs in the nervous system [10].
To further understand the pathophysiology by which
PTPs caused colitis in these KO mice, we performed
substrate-trapping experiments [11] to test whether
E-cadherin and b-catenin were in vivo substrates for
PTPs in the colon. Figure 2C shows that these proteins
might be colonic substrates for PTPs. In support, we
found that E-cadherin is hypertyrosine phosphorylated
in the colons of the PTPRS-KO mice relative to sibling
controls (Figure 2D). Both E-cadherin [12, 13] and b-
catenin [13] are involved in colonic physiology, with a
cadherin-dominant-negative-mouse model expressed
in the gut causing intestinal inflammation [14]. Phos-
phorylation of E-cadherin [15, 16] and b-catenin [17–
19] results in cellular redistribution of E-cadherin and
cell disassociation leading to disassembly of the
adherens junction [20]. Taken together, these findings
point to a potential role for PTPs in maintaining the
adherens-junction proteins E-cadherin/b-catenin in a
dephosphorylated state and, thereby, enhancing
barrier-defense integrity in the colon. Alternatively,
loss of PTPs may lead to the disruption of migration
along the crypt-villus axis and increased apoptosis, sim-
ilar to loss E-cadherin in the cadherin-KO-mouse model
[21, 22]. Because PTPRS is significantly expressed in
the muscularis of the large bowel, it is possible that
PTPs may also be involved in dysmotility seen in IBD
patients [23].
Because the PTPRS gene is located on chromosome
17 in the mouse genome and in a region known to be
associated with colitis in mice [24], we investigated, by
using a candidate-gene approach, whether PTPRS
also played a role in human IBD. Interestingly, PTPRS
is located in a syntenic block that is on human chromo-
some 19p13.3 [25] and that is also associated with
human colitis (IBD6 locus). IBD6 was identified in a
genome-wide scan of Canadian families and demon-
strated linkage to IBD, UC, and CD [26]. The importance
of IBD6 as a susceptibility locus has been subsequently
confirmed by genome scan meta-analysis [27]. To date,
no susceptibility genes for IBD in this locus have been
defined [28, 29]. Although MYO9B (located on chromo-
some 19) showed association with CD and UC, it does
not contribute to the original IBD6 observation of linkage
because of the low contribution of sibling risk [30].
PTPRS is located in the region of maximum linkage
in IBD6 (D19S591/D5S247-GATA21G05) [26]. Todetermine whether PTPRS is a susceptibility gene for
IBD, we first identified 42 SNPs (34 SNPs identified
from the HapMap accounting for all Tag SNPs and
non-Tag SNPs, and eight additional nonsynonomous
SNPs) covering the entire PTPRS gene and flanking re-
gions (chromosome 19, 5140–5259 kb). IBD trios (pa-
tients and parents; 409 nuclear families containing
1276 persons; summarized in Table S1) from the Hospi-
tal for Sick Children and Mount Sinai Hospital in Toronto,
Canada, were the genotyped for 33 of these SNPs (nine
SNPs, including all eight additional nonsynonymous
SNPs and one SNP flanking PTPRS, had minor allele
frequency of <1%).
Initial studies of the 33 SNPs with transmission dis-
equilibrium testing (FBAT-e) showed an association
with IBD and UC (Tables S5 and S6), with no association
with CD (Table S7). Figure 3 shows the linkage-disequi-
librium pattern for all 33 SNPs for UC. We then geno-
typed three SNPs (rs886936, rs17130, and rs8100586)
in an additional 37 UC trios from Pittsburgh and per-
formed a joint analysis by using 164 nuclear families
containing 175 UC-affected offspring (Toronto and
Pittsburgh Trios). Three SNPs, rs886936, rs17130, and
rs8100586, showed significant association with UC
(additive modeling FBAT-e: p = 0.0039, 0.030, and
0.0071, respectively; recessive modeling FBAT-e:
p = 0.0062, 0.050, and 0.00051 respectively). The three-
marker haplotype (rs886936, rs17130, and rs8100586)
for the combined trios was also significant for associa-
tion with UC (HBAT-e; p = 0.009). Although the three
SNPs are in strong linkage disequilibrium with one an-
other, only rs17130 and rs8100586 form a block (block
5; Figure 3). To determine whether either of these two
SNPs can explain the association observed in block 5,
we applied conditional haplotype-based likelihood
testing [31]. This conditional analysis showed that
rs8100586 can explain the total association of these
two SNPs, whereas rs17130 cannot. In addition, we
added rs886936 as an explanatory variable to the single
SNP regression model of rs8100586 to determine
whether these two SNP have an independent effect.
Both rs886936 and rs8100586 showed significant asso-
ciations in the analysis. The additional analyses sug-
gested that rs886936 and rs8100586 affect disease
risk independently, whereas rs17130 has no effect. Per-
mutation testing to account for multiple testing yielded
significant values for the two-independent SNP haplo-
type and rs886936 and rs8100586 singly (p = 0.018,
0.020, and 0.038, respectively; 100,000 permutations
with Haploview). There was no further association with
the risk genotypes and a number of covariants (family
history, Judaism, gender, or disease location; all p >
0.05, Table S2). Similarly, no association was seen within
the subgroup of Crohn’s colitis patients. Further larger
replication studies may provide a specific UC phenotype
not described here and determine whether PTPRS is as-
sociated with Crohn’s colitis. Taken together, the animal
model and genetic studies indicate that PTPRS may be
a susceptibility gene for UC in the IBD6 locus.
These SNPs are located in a physiologically important
region of PTPRS, a region that is highly regulated by
alternate splicing of exon 8 (termed a microexonB
[meB])—a spacer sequence encoding the sequence
ELRE (Figure 4B and Figure S2). To determine whether
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1214Figure 1. Increased Susceptibility to Colitis in PTPs Knockout Mice in Two Experimental Models
(A) Histology results. (Aa) shows the histology of DSS-treated mice H and E staining of the distal colon after 6 days of 3% DSS treatment of wild-
type mice (magnification 103; bottom panel: labeled, +/+) compared with PTPRS-KO (magnification 103; top panel: labeled, 2/2) littermates.
Wild-type mice show crypt thickening associated with DSS-induced colitis. PTPRS-KO mice show severe colitis with profound ulceration and
necrosis of bowel. (Ab) shows the histology score of DSS-treated mice and C. rodentium inoculated mice. All scores are compared to normal
values determined by scoring of ten wild-type mice. The left column shows untreated PTPRS-KO mice. Center columns show a significant
difference in the median histological score of the PTPRS-KO mice compared wild-type mice treated with 3% DSS (16 [IQR 16–17] and 11
[IQR 1.5–12], respectively; p = 0.001, Wilcoxon rank sum test). A similar difference was found between the histological scores after C. rodentium
inoculation of PTPRS-KO and wild-type mice (5 [IQR 4–7] versus 1 [IQR 1–2]; p < 0.001, Wilcoxon rank sum test). (Ac) shows the histology of
C. rodentium inoculated mice. H and E staining of the distal colon 10 days after C. rodentium inoculation of wild-type mice (magnification
253; bottom panel: labeled, +/+) compared with PTPRS-KO (magnification 253; top panel: labeled, 2/2) littermates is shown. Wild-type
mice show crypt hyperplasia associated with colitis. PTPRS-KO mice show substantially increased crypt hyperplasia.
(B) Weight loss of DSS-treated mice and C. rodentium inoculated mice. (Ca) shows that PTPRS-KO mice treated with 3% DSS lost significantly
more weight than the wild-type mice after six days of DSS treatment (p values as shown in the figure, Wilcoxon rank sum). In order to compare the
overall weights of the wild-type and the PTPRS-KO mice, we calculated the area under the curves (AUC) for each observation throughout the time
period. The PTPRS-KO mice had significantly smaller AUC (448 [435–437]) than the wild-type mice (478 [453–481]), implying that overall, the
PTPs Is Associated with Ulcerative Colitis
1215Figure 2. Abnormalities in the Large Bowel
after C. rodentium Inoculation, and PTPs
Substrate Identification
(A and B) TEM of distal colon of PTPRS-KO
mice after C. rodentium inoculation. Trans-
mission electron micrograph of the distal
colon of PTPRS-KO mice, 10 days after
C rodentium infection, is shown. (A) shows
C rodentium in the lumen of the colon (arrow).
(B) shows increased anoikis (arrow). Scale
bars represent 2 mm.
(C) Substrate-trapping assay identifying E-
cadherin and b-catenin as colonic substrates
for PTPs. Catalytically-inactive trapping
mutant of PTPs [GST-sD1(DA)], or wild-type
controls [GST-sD1(WT)], were incubated
with lysates from colons of the PTPRS-KO
mice, and the precipitates were immunoblot-
ted for E-cadherin (left panel) and b-catenin
(right panel). The controls fusion proteins
used for the pulldown assays [GST-
sD1(DA), GST-sD1(WT), or GST alone] are
shown below each panel.
(D) E-cadherin is hyper-Tyr-phosphorylated
in colons of the PTPs-KO mice. Colon from
PTPRS-KO mice (2/2) or wild-type sibling
(Sib) controls were lysed, and proteins in
the lysate were immunoprecipitated (IP) with
either pTyr or E-cadherin antibodies. The
IPs were then immunoblotted with either
phosphotyrosine (anti-pTyr) or E-cadherin
antibodies.the region containing the SNPs found here to be associ-
ated with UC leads to alternative splicing, we compared
genotyped immortalized lymphoblast-cell lines derived
from individuals from the Centre d’Etude du Polymor-
phisme Humain. Thus, we compared three individuals
with the three-marker haplotype associated with UC
with three individuals homozygous for the nucleotide
not associated with UC. mRNA was isolated from the
lymphoblast-cell lines, and a DNA fragment correspond-
ing to amino acids 191–371 of PTPs was amplified with
PCR. All three control individuals had the expected 168
amino acid sequence that was a 100% match with either
isoform-2 or -3 (Figure 4A and Figure S2C). In contrast,the individuals with the three-marker haplotype associ-
ated with UC had a novel splice variant of isoform-1
that removed meB and exon 9, along with the normal
isoforms-2 and -3 (Figure 4A and Figure S2C). This novel
splicing resulted in the deletion of the entire third immu-
noglobulin domain in the ectodomain of the PTPs pro-
tein (Figure 4B). This splice variant of exon 9 is only in-
frame in isoform-1, which is the predominant form of
PTPRS in the colon [32]. Because this splicing does
not occur in the shorter forms of PTPRS (isoform-3
and -4) found in the brain [32], the neurological abnor-
malities associated with PTPRS-KO mice [1, 2] are not
expected or seen in patients with UC. Although thePTPRS-KO mice lost significantly more weight than the KO mice (Wilcoxon rank sum test; p = 0.013). (Cb) shows that PTPRS-KO mice inoculated
withC. rodentium had significant weight loss, whereas the wild-type mice continued to gain weight during the experiment period (p < 0.001 at day
7 and 10, Wilcoxon rank sum test; error bars represent SEM).
(C) Disease activity index (DAI) of DSS-treated mice and C. rodentium inoculated mice. (Ba) shows that the DAI score was significantly higher in
the PTPRS-KO mice compared with the wild-type mice from the second day to the end of DSS treatment (all p < 0.001, Wilcoxon rank sum test).
Control untreated PTPRS-KO and wild-type mice had a DAI score of 0. (Bb) shows that the PTPRS-KO mice had a significantly worse median DAI
score on days 7 and 10 after C. rodentium inoculation (both p < 0.001, Wilcoxon rank sum test; error bars represent SEM).
(D) Bleeding in DSS-treated mice. Four of 11 PTPRS-KO mice (36%) began to bleed within 3 days of DSS treatment compared to none of the wild-
type mice (0/11). After 6 days, all (100%) PTPRS-KO mice compared to only two of the wild-type mice (18%) were bleeding (p < 0.001, log rank
test = 16.9, hazard ratio = 0.1 (95% [CI 0.02–0.25]; error bars represent SEM).
(E) Bacterial translocation in DSS-treated mice and C. rodentium inoculated mice. PTPRS mice treated with 3% DSS (left panel) had significantly
more bacteria translocated to mesenteric lymph nodes compared with the wild-type (9/11 [82%] versus 2/11 [18%]; p = 0.009, Fisher’s exact
test). PTPRS-KO mice inoculated with C. rodentium (right panel) had significantly more bacteria translocated to mesenteric lymph nodes com-
pared with the wild-type (5/13 [39%] versus 0/11 [0%]; p = 0.041, Fisher’s exact test; error bars represent SEM).
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1216Figure 3. LD Plot of SNPs Covering the Entire PTPRS Gene
Linkage-disequilibrium pattern across the PTPRS gene and flanking regions for the 33 SNPs. The values are 100 3 D0 with the blank squares
representing D0 of 1.0. Seven haplotypes are shown as predicted by haploview.
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1217Figure 4. Alternate Splicing of PTPRS
(A) PCR analysis showing alternate splicing of
meB and exon 9. Three healthy control indi-
viduals from the ‘‘Centre d’Etude du Polymor-
phisme Humain’’ (CEPH 1334.13, 1340.11,
and 1340.12) with homozygote C nucleotide
at rs8100856 and either GG or AG at
rs17130 and rs886936 were compared with
three individuals (CEPH 1340.01, 1344.13,
and 1362.02) with homozygote nucleotide A
for all SNPs resulting in the three-marker hap-
lotype found to be associated with UC. PCR
product isolated from the control individuals
(left) and the three-marker haplotype associ-
ated with UC (right) are shown. The large frag-
ment corresponds to isoform 2 and 3, and the
smaller fragment corresponds to the alter-
nate splicing of exon 8 and 9 in isoform 1.
(B) Novel alternate splicing of meB and exon
9. Alternate splicing in rs17130, rs886939,
and rs8100586 three-marker haplotype is
shown. Exon 9, Ig-like domain 3 (Ig3, shown
in orange), is spliced out along with meB
(yellow, usually found in this isoform-1). This
splicing variant is only inframe in isoform-1.function of the Ig-like domain of PTPs is unknown, we
speculate that it plays a role in either dimerization or
ligand binding of PTPs [33], similar to the alternate splic-
ing in PTPRC (CD45) that is associated with multiple
sclerosis [34, 35]. These results indicate that these poly-
morphisms may disrupt the balance of splice variants in
the colon and that alternate splicing of exon 9 may help
explain the association with colitis described here.
In summary, we show here that SNPs flanking exon 8
within the PTPRS gene have significant association with
UC. The three-marker haplotype associated with UC
results in novel alternate splicing of meB and exon 9.
This novel splicing completely removes the third immu-
noglobulin like (Ig-like) domain of PTPs, possibly alter-
ing ligand recognition or dimerization that may be
important for ligand binding. PTPRS is known to be
expressed in the human colon [32], and we demonstrate
that PTPRS-KO mice develop spontaneous mild colitis
and are susceptible to induced colitis. Taken together,
our work identifies PTPRS as a novel gene associated
with ulcerative colitis and provides important insight
into the pathogenesis of this disease.
Supplemental Data
Experimental Procedures, two figures, and seven tables are avail-
able at http://www.current-biology.com/cgi/content/full/17/14/
1212/DC1/.
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